The tweet was deleted by the author.
But we saved everything 🙂.
Oric Pharmaceuticals announced that two preclinical abstracts detailing the potential of rinzimetostat (ORIC-944) for prostate cancer treatment have been accepted for poster presentation at the AACR2026 annual meeting scheduled for April 17-22, 2026.
The abstracts support the positioning of rinzimetostat as a best-in-class therapeutic candidate. The American Association for Cancer Research (AACR) conference is a prominent platform for unveiling new cancer research findings, highlighting Oric Pharmaceuticals' role in advancing prostate cancer therapies.
The company's heightened profile at AACR2026 follows a period of internal focus, underscored by initiatives such as its recent emphasis on team recognition and wellness, as highlighted during Oric Pharmaceuticals' observance of Employee Appreciation Day. Such efforts reflect a comprehensive approach to both scientific innovation and employee engagement as Oric advances its therapeutic pipeline.